The pharmaceuticalindustry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms and the gravity of unmet need, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Adenovirus-based medicinal compositions. Buy the report here.

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

110 innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

Adenovirus-based medicinal compositions is a key innovation area in pharmaceutical

Adeno-associated virus (AAV) is a DNA virus that can be engineered to deliver DNA to target cells. AAV belongs to the parvovirus family and consists of a single-stranded DNA genome of approximately 4.8 kilobases (kb). Recombinant AAV (rAAV), which lacks viral DNA, is engineered to deliver its DNA payload into the nucleus of a cell. AAV vectors are very stable and can withstand wide fluctuations in temperature and pH with no loss in activity, which makes them an attractive candidate for gene therapies and recombinant vector vaccines.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 30+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of adenovirus-based medicinal compositions.

Key players in adenovirus-based medicinal compositions – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to adenovirus-based medicinal compositions

Company Total patents (2010 - 2021) Premium intelligence on the world's largest companies
PsiOxus Therapeutics 219 Unlock company profile
Targovax 72 Unlock company profile
Vascular Biogenics 55 Unlock company profile
EpicentRx 54 Unlock company profile
DNAtrix 51 Unlock company profile
Genemedicine 40 Unlock company profile
Hangzhou Converd 29 Unlock company profile
Johnson & Johnson 29 Unlock company profile
Institut Catala d'Oncologia 21 Unlock company profile
Valo Therapeutics 20 Unlock company profile
CG Oncology 20 Unlock company profile
BioLineRx 18 Unlock company profile
TILT Biotherapeutics 17 Unlock company profile
Bayer 17 Unlock company profile
Ixogen 16 Unlock company profile
Beijing Bio-Targeting Therapeutics Technology 13 Unlock company profile
Mayo Clinic 12 Unlock company profile
Merck & Co 11 Unlock company profile
Memorial Sloan Kettering Cancer Center 11 Unlock company profile
Momotaro-Gene 11 Unlock company profile
Synthetic Biologics 10 Unlock company profile
Bionoxx 9 Unlock company profile
Hybrid BioSystems 9 Unlock company profile
Trieza Therapeutics 8 Unlock company profile
Shanghai Yuansong Biotechnology 7 Unlock company profile
Memgen 6 Unlock company profile
Samyang Holdings 6 Unlock company profile
Coastar Therapeutics 6 Unlock company profile
AdCure Bio 6 Unlock company profile
Cedars-Sinai Health System 6 Unlock company profile
Erasmus MC 5 Unlock company profile
ORCA Therapeutics 5 Unlock company profile
National Cancer Center 5 Unlock company profile
UAB Research Foundation 5 Unlock company profile
Amgen 5 Unlock company profile

Source: GlobalData Patent Analytics

PsiOxus Therapeutics is one of the most important players concerning innovation surrounding adenovirus-based therapeutics. The company is largely involved in the cancer immuno-oncology. Its T-SIGn viral vector platform delivers multiple transgene payloads and re-programmes the tumour microenvironment of both primary and metastatic tumours. The platform enables intravenous (IV) delivery of multi-armed genetic payloads to tumours and metastases.

In terms of application diversity, PTC Therapeutics Inc is the top company followed by EpicentRx Inc and AFFiRiS AG. By means of geographic reach, Max-Planck-Gesellschaft holds the top position. Hybrid BioSystems, Ltd and MorphoSys AG are in the second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.